Table 3.
Regional 5-HT synthesis ratesa (mean± SD [pmol/g/min]) in sham rats treated with either vehicle (SVV), citalopram alone (SCV) or in combination with pindolol (SCP).
| Region | Predominant Nucleus of Origin | SVVa (n=9) |
SCVa (n=9) |
% change in SCV relative to SVV | SCPa (n=9) |
% change in SCP relative to SCV |
|---|---|---|---|---|---|---|
| aPCX | DR | 21 ± 6 | 34 ± 8 | 61* | 45 ± 10 | 32# |
| pPCX | DR | 27 ± 6 | 42 ± 7 | 55* | 52 ± 10 | 22# |
| FCX | DR | 18 ± 6 | 38 ± 9 | 112* | 56 ± 13 | 46# |
| SCX | DR | 12 ± 5 | 32 ± 8 | 164* | 52 ± 10 | 61# |
| AudCX | DR | 13 ± 6 | 43 ± 7 | 238* | 60 ± 11 | 39# |
| VCX | DR | 19 ± 5 | 43 ± 7 | 129* | 60 ± 10 | 40# |
| BNST | DR | 31 ± 6 | 41 ± 9 | 34* | 53 ± 11 | 30# |
| Nacc | DR | 40 ± 7 | 52 ± 9 | 31* | 56 ± 11 | ns |
| CPL | DR | 22 ± 7 | 35 ± 8 | 59* | 49 ± 9 | 39# |
| CPM | DR | 34 ± 8 | 46 ± 9 | 37* | 58 ± 11 | 25# |
| CPV | DR | 34 ± 8 | 50 ± 8 | 47* | 54 ± 11 | ns |
| GP | DR | 21 ± 7 | 37 ± 6 | 78* | 47 ± 9 | 30# |
| AC-Amyg | DR | 27 ± 6 | 43 ± 8 | 61* | 55 ± 10 | 29# |
| CN-Amyg | DR | 28 ± 6 | 47 ± 6 | 68* | 59 ± 13 | 26# |
| BLN-Am | DR | 30 ± 6 | 52 ± 7 | 71* | 59 ± 9 | ns |
| PV-Thal | DR | 25 ± 8 | 42 ± 9 | 69* | 71 ± 13 | 69# |
| SNc | DR | 20 ± 6 | 38 ± 9 | 87* | 58 ± 12 | 52# |
| LC | DR | 28 ± 8 | 47 ± 8 | 69* | 61 ± 8 | 30# |
| MOA | MR | 36 ± 5 | 46 ± 8 | ns | 55 ± 10 | 20# |
| MOCX | MR | 26 ± 6 | 42 ± 8 | 59* | 49 ± 10 | ns |
| IFLCX | MR | 32 ± 5 | 41 ± 8 | 29* | 54 ± 10 | 30# |
| CgCX | MR | 21 ± 6 | 35 ± 8 | 67* | 48 ± 11 | 39# |
| SCH | MR | 36 ± 7 | 46 ± 12 | ns | 60 ± 14 | 30# |
| Hipp-d | MR | 30 ± 6 | 50 ± 7 | 66* | 56 ± 9 | ns |
| DG | MR | 29 ± 6 | 50 ± 7 | 75* | 56 ± 9 | ns |
| CA3 | MR | 46 ± 16 | 55 ± 7 | ns | 51 ± 10 | ns |
| DR | 99 ± 11 | 83 ± 11 | -16* | 90 ± 15 | ns | |
| MR | 69 ± 10 | 59 ± 10 | ns | 81 ± 12 | 38* | |
Region names: medal anterior olfactory area (MOA); cortical areas- medial orbital (MOCX), infralimbic (IFLCX), anterior cingulate (CgCX), anterior and posterior pyriform (aPCX and pPCX), primary motor (FCX), somatosensory (SCX), auditory (AudCX), and visual (VCX); amygdala areas- anterior cortical (AC-Amyg), central nucleus (CN-Amyg), basolateral nucleus (BLN-Amyg); subcortical areas- bed nucleus of the stria terminalis (BNST), nucleus accumbens (Nacc), caudate-putamen (lateral-CPL; medial-CPM; ventral-CPV), globus pallidus (GP), paraventricular thalamus (PV-Thal), suprachiasmic nucleus (SCH), dorsal hippocampus (Hipp-d), dentate gyrus (dorsal; DG), CA3 (dorsal; CA3), substantia nigra compacta (SNc), locus coeruleus (LC), median raphe (MR), dorsal raphe (DR).
Significant difference between SVV and SCV groups.
Significant difference between SCV and SCP groups.
ns, not significant.